Halozyme Therapeutics Stock Jumps After Earnings, Bull Note

A short squeeze could push HALO even higher

by Patrick Martin

Published on Feb 21, 2018 at 10:30 AM

Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock is up 3.1% to trade at $19.11 this morning, after Canaccord Genuity upped its price target on the oncology specialist to $21 from $19. The analyst in coverage is encouraged by last night's fourth-quarter and full-year results, which showed progress in HALO's ENHANZE portfolio. 

HALO stock rode a mid-September bull gap past former resistance near the $15 level, and climbed to a two-year high of $21.13 on Dec. 29. The equity pulled back from here, due in part to a bearish note from Deutsche Bank. And while the shares eventually bounced from their rising 180-day moving average, they are still down 5.9% in 2018.

Despite today's bullish brokerage note, analyst attention has been mixed. While five brokerages covering HALO rate it a "strong buy," the other four maintain a "hold" or "sell." The average 12-month price target of $21.91, meanwhile, represents expected upside of 15.2% to the stock's current perch.

Short sellers have been in cover mode since these bearish bets topped out at a record high of 25.30 million shares last March. In the most recent reporting period alone, short interest plunged 12.05% to 10.23 million shares, though this still represents 6.4 times HALO stock's average daily pace of trading.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


With This Lithium Stock, It Will Be Better to Be Too Early Than Too Late
Click to continue to advertiser's site.
Tesla Drops Prices to Boost Demand
Tesla is cutting North American and Chinese prices by as much as 6%
DPZ Sizzles After Same-Quarter Sales Bounce
Comparable-store sales in the U.S. rose by 14% during the first two months of the current quarter
With This Lithium Stock, It Will Be Better to Be Too Early Than Too Late
Click to continue to advertiser's site.